Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 4 2Phase 2 2Phase 1 2Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 13INDUSTRY 2UNKNOWN 1NIH 1

Study Type

Interventional 2

Sponsor

Conditions

Vomiting 2Nausea 2Neoplasms 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × Ondansetron × Clear all
NCT00285051 2020-12-23

Comparison of Delta-8-THC to Ondansetron in the Prevention of Acute Nausea From Moderately Emetogenic Chemotherapy

Rafa Laboratories

Phase 2 Terminated
6 enrolled

Nausea, Neoplasms, Vomiting

NCT00169572 2010-05-10

Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy

GlaxoSmithKline

Phase 2 Completed
492 enrolled

Nausea, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡